PRINCESS MARGARET CANCER CENTRE INNOVATION ACCELERATION FUND OVERVIEW

Overview

The Princess Margaret Cancer Centre is the largest cancer centre in Canada and one of the top five cancer research centres in the world. With the goal of improving the lives of people affected by cancer, the scientists and clinicians at Princess Margaret are continuously advancing our understanding of cancer biology and discovering opportunities for new treatments, and enhancements to cancer care.

Translating research discoveries to achieve maximum patient impact (e.g. therapies/services) means validation for their safe and effective use, which requires significant financial commitment, and is usually achieved by working with a commercial partner to help  establish safety and effectiveness, which includes licensing of UHN technologies to allow their continued validation/development. Historically, funding needed to support the development of early stage research/promising technologies, has been lacking. The Princess Margaret Cancer Centre’s Innovation Acceleration Fund (IAF) has been established precisely to address this funding gap. Its objective is to accelerate research discoveries to a point where their commercial viability can be demonstrated, thus enabling initial stages of development of therapeutics/services that can eventually be used by patients.  

IAF funding is made possible by the generous support of the Princess Margaret Cancer Foundation and is administered by the Technology Development & Commercialization office (TDC) at UHN. TDC ensures alignment between IAF and UHN’s Intellectual Property Policy and actively participates in strengthening the business and commercialization aspects of IAF proposals and presentations.

 

Background

The Princess Margaret Cancer Centre’s Innovation Acceleration Fund (IAF) has been established to advance innovative research with promising commercial potential along the path towards commercialization. The IAF program solicits and awards milestone based proposals of up to $250,000 in support of UHN innovations in anticipation of a future commercialization event.

Translational research activities considered eligible, but are not limited to:

  • Prototype development
  • Generation of in-vivo data
  • Reduction to practice
  • Proof-of-concept studies
  • Clinical demonstration
  • Scale up required for clinical phase work

Objective

The primary goal of the IAF is to support the advancement of research from the Princess Margaret Cancer Centre towards commercialization, in order to deliver advanced health care.

Eligibility

To be eligible for the IAF, the lead applicant must be both the principal inventor and hold an appointment with Princess Margaret Cancer Centre. Please refer here for further details on eligibility criteria.

The Role of TDC 

Upon submission by an eligible applicant of an Investment Proposal Form, each proposal is assigned a TDC sponsor to champion the technology, including by providing market and commercialization strategy input to the presentation materials, and jointly presenting the project to the IAF Board. Prospective applicants are encouraged to contact TDC prior to submitting a proposal, for guidance on intellectual property and commercialization considerations.

Questions? Contact: 

Brian Bobechko

Business Development and Commercialization Principal

IAFinfo@tdc.uhnresearch.ca